undamentalytics Newsletter
Sign in

Embecta Corp. income statement

In fiscal 2025, Embecta Corp. reported revenue of $1.08bn, down 3.8% on the year before, operating income of $242m (a 22.4% margin) and net income of $95.4m, or $1.62 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Revenue1,0861,1651,1301,1211,1231,0801,019
Cost of revenue323365355371388404417
Gross profit763800775750735677601
Research and development61636785793720
Selling, general and administrative215240295341365332319
Operating income487492310222167242224
Income before tax48649525710644136125
Income tax58803335−344138
Net income42841522470789588
Diluted EPS$7.50$7.28$3.89$1.22$1.34$1.62$1.48
Diluted shares (average)57m57m57m58m58m59m59m
EBITDA525530341254203283268

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EMBC vs UFPTEMBC vs ICUIEMBC vs ORGO

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from Embecta Corp.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Embecta Corp.